Home
Live Updates
JW Therapeutics: Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress : comparemela.com
JW Therapeutics: Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology
Related Keywords
China ,
Hong Kong ,
Shanghai ,
Markj Gilbert ,
A Bristol Myers Squibb ,
Ltd The Company ,
Prnewswire Jw Cayman Therapeutics Co ,
China National Medical Products Administration ,
National Significant New Drug Development Program ,
Rheumatology Congress ,
Clearing Limited Hkex ,
European Alliance Of Associations ,
Investigational New Drug ,
Biologics License Application ,
Chief Medical Officer ,
Juno Therapeutics ,
Bristol Myers Squibb ,
Stock Code ,
Hong Kong Exchanges ,
Clearing Limited ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.